Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner Enigma Biomedical USA, Inc. (Enigma) and the University of Wisconsin–Madison (UW–Madison) have announced a new partnership aimed at advancing the development of next-generation Positron Emission Tomography (PET) imaging and fluid biomarkers…
Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025 Massive Bio is proud to announce its inclusion in the White House Office of Science & Technology Policy’s upcoming Cancer Moonshot Fact Sheet, highlighting its innovative…
Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical Mainstay Medical Holdings plc reports today the publication of positive one-year results from the RESTORE randomized clinical trial of ReActiv8®, a treatment for intractable chronic low back pain. The…
Zai Lab Reports Positive TIVDAK Results in China for Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating that TIVDAK (tisotumab vedotin)…
GenSight Biologics Announces Groundbreaking 5-Year Outcomes for Unilateral LUMEVOQ® Gene Therapy GenSight Biologics (Euronext: SIGHT) has announced the publication of five-year follow-up data for patients treated with its investigational gene therapy, LUMEVOQ® (lenadogene nolparvovec), for Leber Hereditary Optic Neuropathy (LHON).…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented an exciting update to the investment community during the 43rd annual J.P. Morgan Healthcare Conference. In addition to announcing its preliminary financial results for the fourth quarter and…
Therapeutics Company Tune Raises Over $175M in Series B to Advance Epigenome Editing Tune Therapeutics, a leading company in the field of epigenome editing, today revealed the successful completion of a financing round totaling over $175 million. The funding was…
Alnylam Reports Q4 and Full Year 2024 Revenue and 2025 Guidance Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, today announced preliminary global net product revenues for the fourth quarter and full year of 2024, covering…
Hologic Reports Preliminary Revenue Results for Q1 Fiscal 2025 Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and diagnostic solutions, today announced its preliminary revenue results for the first quarter of fiscal 2025, which ended on December 28,…
Results: Castle Biosciences Reports Preliminary Q4 and 2024 Performance Castle Biosciences, Inc. (Nasdaq: CSTL), a company dedicated to improving patient care through innovative tests, today announced preliminary unaudited performance results for the fourth quarter and full year ending December 31,…
Research Network: N-Power Medicine Acquires Syapse for Oncology N-Power Medicine, a leader in transforming the clinical trial process, has announced the acquisition of Syapse Holdings Inc. (“Syapse”), a trailblazer in precision medicine solutions for community cancer centers. By integrating Syapse…
Gilead and LEO Pharma Partner on Oral STAT6 Program Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today revealed a strategic partnership aimed at fast-tracking the development and commercialization of LEO Pharma’s small molecule oral STAT6 (Signal Transducer and Activator…